Clinical trials: Neoplasms, Metastatic
Non Small Cell Lung Cancer
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
- Trial name
- NCT07070440
- Testing
- DZD6008, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Dizal Pharmaceuticals
Colon Adenocarcinoma, Rectal Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
- Trial name
- NCT06997497
- Testing
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium
- Where
- 244 sites in United States, Argentina and 27 more
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Rectal Cancer, Colon Cancer
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
- Trial name
- NCT00101894
- Testing
- FOLFOX-4, AMG 706, Panitumumab (Part 1a only)
- Volunteers
- 119 people
- Sponsor
- Amgen
Metastatic Castration-Resistant Prostate Cancer
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
- Trial name
- NCT02711956
- Testing
- ZEN003694, Enzalutamide
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Zenith Epigenetics
Breast Cancer, Hormone Receptor Positive Tumor
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
This study is designed to evaluate the efficacy and safety of first-line treatment ribociclib in combination with aromatase inhibitor (AI) or fulvestrant OR capecitabine with bevacizumab OR paclitaxel with / without bevacizumab…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
- Trial name
- RIBBIT (NCT03462251)
- Testing
- Ribociclib and aromatase inhibitor or fulvestrant, Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
- Where
- 27 sites in Germany
- Volunteers
- 41 people
- Sponsor
- iOMEDICO AG
Colorectal Cancer Metastatic
Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
Primary Objectives: Study Part 1: To determine the recommended dose for the aflibercept, oxaliplatin and capecitabine (XELOX) combination to be used in the Part 2 of the study.
- Trial name
- AMOR (NCT01955629)
- Testing
- Aflibercept AVE0005, Oxaliplatin, Capecitabine
- Where
- 2 sites in Italy
- Volunteers
- 4 people
- Sponsor
- Sanofi
Metastatic Breast Cancer
Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study
The goal of this clinical trial is to learn the comparative pharmacokinetic parameters between the test product and the Reference listed drug in healthy female volunteers The main question[s] it aims to answer are: To assess the…
- Trial name
- NCT06074757
- Testing
- Fulvestrant injection
- Where
- Jordan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Non-small Cell Lung Cancer
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
This is a randomized, open-label, multicenter Phase 3 clinical study to evaluate SKB264 monotherapy versus pemetrexed in combination with platinum in subjects with locally advanced or metastatic non-squamous NSCLC with EGFR…
- Trial name
- NCT05870319
- Testing
- SKB264, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HER2-positive Breast Cancer
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.
- Trial name
- NCT06265428
- Testing
- DB-1303/BNT323, T-DM1
- Where
- 48 sites in China
- Volunteers
- 228 people
- Sponsor
- DualityBio Inc.
Breast Neoplasms
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated…
- Trial name
- NCT02258451
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Exemestane, Everolimus
- Where
- 92 sites in United States, Austria and 15 more
- Volunteers
- 283 people
- Sponsor
- Bayer
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05420545
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Treatment for Metastatic or Locally Advanced Cervical Cancer
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure.
- Trial name
- NCT01613677
- Testing
- BKM120
- Where
- Brazil
- Sponsor
- Novartis Pharmaceuticals
Non-Squamous Non-small Cell Lung Cancer
Phase 3 Clinical Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer…
- Trial name
- NCT05184712
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Akeso
Advanced Urothelial Carcinoma
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or…
- Trial name
- NCT06079112
- Testing
- 9MW2821, Toripalimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Hepatic Carcinoma
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.
- Trial name
- NCT01770431
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Gastrointestinal Stromal Tumor
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.
- Trial name
- NCT01039519
- Testing
- Ganetespib
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Synta Pharmaceuticals Corp.
Advanced Tumors, Lymphoma
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in patients with locally advanced/metastatic solid tumors or lymphoma.Up to 150 patients will be included in this study.
- Conditions
- Advanced Tumors, Lymphoma, Metastatic Tumors
- Trial name
- HLX301 (NCT05390528)
- Testing
- HLX301
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer
Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
LEP-ETU is a novel, proprietary delivery system of paclitaxel developed by NeoPharm, Inc. Paclitaxel (currently marketed as Taxol) is an anti-microtubular network agent and is active in a broad spectrum of malignancies.
- Trial name
- NCT01190982
- Testing
- LEP-ETU
- Where
- 3 sites in India
- Volunteers
- 70 people
- Sponsor
- INSYS Therapeutics Inc
Neoplasm
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
The purpose of this study is to determine the highest dose of Liposome Entrapped Paclitaxel Easy to Use formulation (LEP-ETU) that can be safely administered by an intravenous infusion to patients with advanced cancer.
- Trial name
- NCT00080418
- Testing
- Liposome Entrapped Paclitaxel Easy to Use
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.